AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00454792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restitution
Description: Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
Study NCT01664104 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
Study NCT02540642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: METHYLCOBALAMIN 500 micrograms
Description: Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
Study NCT03586167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID014341 contact lenses
Description: Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
Study NCT03586167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel contact lenses
Study NCT04245319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
Study NCT04245319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B
Description: Patients receive nbUVB session 3 times per week
Study NCT04245319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Narrow band ultraviolet B
Description: Patients receive nbUVB session 3 times per week
Study NCT03213470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Study NCT02795650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalised treatment
Description: Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
Study NCT02795650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment chosen per investigator´s judge
Description: Investigators are allowed to chose what they consider the best standard treatment option for their patients.
Study NCT03673709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Care
Description: Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
Study NCT01571037 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: inhaled nebulized milrinone
Description: 0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
Study NCT04363086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iFightDepression online self-help tool
Description: Computerized cognitive behavior therapy
Study NCT04363086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: TAU
Study NCT02633501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT04363086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone call
Description: phone call
Study NCT01488305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP (micro-nutrient powders)
Description: MNP is added to explore the additional value of MNP in existing AAMA program
Study NCT01488305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAMA project activities (HFP and IYCF BCC)
Description: This is the existing AAMA program
Study NCT01235624 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Study NCT02839967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
Study NCT02839967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation placebo
Description: The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
Study NCT04413240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: * VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved.
Study NCT04413240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
Study NCT01125176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 50 mg oral dosing every other day
Study NCT01125176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: varying oral doses every other day (max 25 mg/day)
Study NCT01125176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
Study NCT03796156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75mg low dose non enteric coated or dispersible
Study NCT02648035 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Subcutaneous Tocilizumab according to approved label.
Study NCT04152005 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
Study NCT03544671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT03544671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study NCT03781882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma infiltration in the wound edges
Description: platelet rich plasma will be injected in the wound edges
Study NCT03781882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of wound without platelet rich plasma infiltration
Description: No infiltration of platelet rich plasma is done
Study NCT00237796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Description: Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
Study NCT00237796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Focused Supportive Contact (GFSC)
Description: Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
Study NCT00549237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose load (Nutricia)
Description: Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
Study NCT00549237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post operative early enteral feeding
Description: Enteral feeding starting 6 hours post surgery
Study NCT03581773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 5 mg pr day for 12 weeks
Study NCT03581773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 1 placebo pill pr day for 12 weeks
Study NCT01204840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
Study NCT01204840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patch protocol
Description: Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped.
Study NCT02013024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation technique
Study NCT04492397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Description: Subjects will be randomized to wear test lenses.
Study NCT04492397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens
Description: Subjects will be randomized to wear test lenses.
Study NCT04492397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact Lens
Description: Subjects will be randomized to wear control lenses.
Study NCT04492397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens
Description: Subjects will be randomized to wear control lenses.
Study NCT00109850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
Study NCT00109850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
Study NCT00109850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
Study NCT00109850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
Study NCT01150162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide and Omeprazole
Description: open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
Study NCT01150162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
Study NCT03721627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Direct acting anti HCV drugs
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: oral doses
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral doses
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 1000-1200mg/day po
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200mg/day po
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: 1000-1200mg/day po
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses
Study NCT01185860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir
Description: oral doses
Study NCT03747185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT03747185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT03747185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT03747185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study NCT01692886 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
Study NCT01692886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
Study NCT01692886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
Study NCT01692886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
Study NCT01785394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 grass allergen extract
Description: 30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
Study NCT01785394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 grass allergen extract
Description: 30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
Study NCT01212549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunocryosurgery
Description: 2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
Study NCT01212549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoimmunotherapy
Description: Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
Study NCT01042678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye
Study NCT01611610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional tests
Description: The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module
Study NCT01611610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional tests
Description: The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module
Study NCT01977209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gossypol
Study NCT01977209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02407951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBIT group
Description: Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians.